Retatrutide 10mg

What is Retatrutide (10 mg)?

Retatrutide (10 mg) is a synthetic peptide engineered as a triple receptor agonist. It targets glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors in experimental systems.

Unlike single-pathway peptides, Retatrutide is designed to engage multiple metabolic pathways. Its extended amino acid sequence, along with specific substitutions such as α-aminoisobutyric acid (Aib) residues, enhances structural stability and receptor interaction in controlled research environments.

In laboratory and preclinical studies, Retatrutide is investigated for its ability to activate interconnected endocrine signaling networks. It helps researchers explore how coordinated receptor activation influences glucose metabolism, lipid regulation, energy expenditure, and hormonal communication in cellular and animal models.

Product Specifications

• CAS Number: 2381089-83-2
• Synonyms: Retatrutide acetate, LY3437943
• Peptide Sequence:
  Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (Sodium salt)
• Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
• Molecular Weight:33 g/mol
• Subcategory: Weight Loss & Metabolic Peptides
• Purity: ≥95% (verified by HPLC and mass spectrometry)
• Packaging Format: (10 mg) lyophilized powder in sealed research-grade vial
• Storage Conditions: Store refrigerated at 2–8 °C. For periods of non-use, maintain at ≤–20 °C. Protect from light
• Intended Use: For Laboratory Research Use Only

Key Characteristics of Retatrutide (10 mg)

• Triple-Receptor Research Peptide: Designed for experimental engagement of GLP-1, GIP, and glucagon receptors.
• High Molecular Complexity: Suitable for studying prolonged receptor interactions and downstream signaling.
• Stability-Enhanced Modifications: Includes Aib substitutions to enhance resistance to enzymatic degradation.
• Lyophilized Presentation: Freeze-dried format supports structural preservation and controlled reconstitution.
• High Analytical Purity: Typically ≥95%, confirmed through chromatographic and spectrometric validation.
• Multi-System Research Utility: Useful in metabolic, endocrine, and energy-regulation laboratory models.

How Retatrutide (10 mg) Supports Research

Retatrutide (10 mg) is used in research to investigate coordinated metabolic signaling across multiple hormonal pathways. By activating GLP-1, GIP, and glucagon receptors, it enables researchers to examine how overlapping endocrine systems regulate glucose uptake, nutrient distribution, and cellular energy utilization.

In controlled experimental environments, investigators study its receptor-binding properties, intracellular signaling, and effects on metabolism-related gene expression. Its multi-agonist design facilitates comparative studies of single-pathway peptides versus integrated receptor stimulation models.

Given its multi-target structure, Retatrutide is particularly useful for studying complex metabolic adaptations and endocrine network interactions in preclinical research.

Research Applications & Usage Information

Retatrutide (10 mg) is commonly used in laboratory research involving:

• GLP-1 receptor signaling studies
• GIP receptor pathway investigations
• Glucagon receptor activation models
• Energy homeostasis and metabolic regulation research
• Endocrine communication and hormone interaction studies
• Comparative peptide agonist evaluations
• In vitro cellular signaling assays
• Preclinical metabolic and endocrine animal models

All use is strictly limited to controlled in vitro or preclinical experimental settings.

Handling and Storage Recommendations

• Store unopened vials at 2–8 °C (≤–20 °C for long-term storage). Protect from light.
• Keep vial sealed until reconstitution.
• Minimize exposure to heat, humidity, and direct light.
• Allow vial to equilibrate before opening to prevent moisture condensation.
• After reconstitution, store at 2–8 °C per laboratory protocol.
• Avoid repeated freeze–thaw cycles to preserve peptide integrity.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013
2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
3. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. doi:10.1038/s41591-024-03018-2
4. Ma J, Hu X, Zhang W, Tao M, Wang M, Lu W. Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. Endocrine. 2025;87(1):159-169. doi:10.1007/s12020-024-03998-8